EWTX Edgewise Therapeutics, Inc.
EWTX Edgewise Therapeutics, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-10-16 1 neutral converging
POC $23.84 · VWAP $33.08 · +12.4% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, Officer + 3 others sold $1.9M, Aug 14
Coverage
1 watchlist
EWTX Price Structure
Loading timeframes…
Peers
Every watchlist EWTX belongs to, members best 30-day change first — EWTX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: diluted EPS -$0.53, net income -$57M (SEC filing). Across the print the stock moved -3.3% (close before → first close after).
full note →Against street estimates
How EWTX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
EWTX research tape
81 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.